-
<![CDATA[SHARON Trial Offers a Potential Approach for Advanced Pancreatic Cancer ]]>
16 Dec 2025 17:59 GMT
… its significance in the treatment of advanced pancreatic cancer?
O'Reilly: The … -based therapies and classes of drugs called PARP inhibitors and alkylating … infection, from pharmacy for safe drug preparation and delivery, from nursing …
-
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
16 Dec 2025 20:27 GMT
… .
Translational analysis revealed that pelareorep treatment led to notable increases in … Track and Orphan Drug designations from the FDA for pancreatic cancer.
CEO Jared … mutant-selective PI3Kα inhibition, with treatment-related adverse events that were …
-
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
16 Dec 2025 13:40 GMT
… the German Federal Institute for Drugs and Medical Devices (BfArM). The … in locally advanced pancreatic cancer - a disease with limited treatment options and … product candidate for locally advanced pancreatic cancer. For more information please visit …
-
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
16 Dec 2025 17:18 GMT
… . Translational analysis revealed that pelareorep treatment led to notable increases in … Track and Orphan Drug designations from the FDA for pancreatic cancer. CEO Jared … mutant-selective PI3Kα inhibition, with treatment-related adverse events that were …
-
GC Biopharma’s Neulapeg cuts severe neutropenia to near zero in pancreatic cancer trial
16 Dec 2025 09:01 GMT
… of its neutropenia treatment, Neulapeg (pegteograstim), in pancreatic cancer patients in the … neutropenia treatment developed independently by GC Biopharma. The drug is … advanced or metastatic pancreatic cancer to either a Neulapeg treatment group (38 …
-
Popular weight-loss drugs may lower cancer risk, finds large study
16 Dec 2025 15:47 GMT
… GLP-1 weight-loss medications might dramatically reduce the … in gallbladder cancer, meningioma, pancreatic cancer, and liver cancer. For … drugs vs metformin
Metformin is often the first drug … assigning treatments randomly.The results suggest that GLP-1 drugs …
-
TP53 mutations emerge as predictor of chemo response in pancreatic cancer
16 Dec 2025 02:58 GMT
… to decrease or worsening.
“Advanced pancreatic cancer treatment needs a personalized approach due … markers that predict treatment effectiveness, enabling personalized treatment for more pancreatic cancer patients,” Professor …
-
Phil Rivers Tech Raises Eight-Figure Series A1 to Advance AI4S-Driven Drug Innovation
16 Dec 2025 11:49 GMT
… used to advance core drug pipelines, expand global … breakthroughs: discovery of novel drug targets, identification of new … Hospital, the platform’s drug response predictions for eight … s first-in-class pancreatic cancer drug candidate PR00012 has entered …
-
Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer
15 Dec 2025 15:00 GMT
AGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) in collaboration with the Brush and Key Foundation, today announced the publication of a peer-reviewed research article in the International Journal of …
-
BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
15 Dec 2025 14:00 GMT
… Application for YntraDose® in the treatment of unresectable Locally Advanced Pancreatic … patients facing unresectable locally advanced pancreatic cancer - one of the most … for the localised and targeted treatment of unresectable solid tumours called …
About
© 1995-2025